The Cancer Epigenetics Society is very happy to announce the appointment of Dr. Cigall Kadoch to the Editorial Board of the Cancer Epigenetics journals series.
Dr. Kadoch is an expert of ATP-dependent mammalian SWI/SNF chromatin remodeling machineries, with a particular interest in locus-specific and genome-wide modulation by BAF complexes in cancer.
Dr. Kadoch is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Assistant Professor of Pediatric Oncology at the Dana-Farber Cancer Institute (Boston, MA, USA). She is also a Member in Chemical Biology at the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard University (Cambridge, MA, USA).
Dr. Kadoch received her PhD from Stanford University wherein she elucidated the molecular mechanisms of synovial sarcoma-specific oncogenic fusion disruption of SWI/SNF (Cell 153:71). She continued her work as a Postdoctoral Fellow at Stanford University School of Medicine working with Dr. Gerald Crabtree, a Howard Hughes Medical Institute (HHMI) investigator, and Member of the National Academy of Sciences, USA.
Dr. Kadoch has received several accolades, including being listed by MIT in the 35 innovators under 35 and by Forbes in the 30 under 30. She was also recognized as a Pew-Stewart Scholar in Cancer Research, and received the NIH Director’s New Innovator Award.
This is the first time that Dr. Cigall Kadoch accepts to serve on the Editorial Board of a journal. We at the Cancer Epigenetics Society feel privileged and are excited to work with her alongside Editor-in-Chiefs Dr. Sharon Dent (MD Anderson Cancer Center) and Dr. Peter Jones (Van Andel Research Institute). We very much look forward to her insights in both synovial sarcomas and chromatin remodeling complexes, to publish the most thought-provoking advances in these and related fields in the Cancer Epigenetics journals series (Cancer Epigenetics Society news, July 12, 2017).
